Comparative Pharmacology
Head-to-head clinical analysis: NORCEPT E 1 35 21 versus NORETHIN 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORCEPT E 1 35 21 versus NORETHIN 1 35E 28.
NORCEPT-E 1/35 21 vs NORETHIN 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
Combination estrogen-progestin oral contraceptive. Ethinyl estradiol suppresses FSH and LH, preventing ovulation. Norethindrone alters cervical mucus and endometrial lining, inhibiting sperm penetration and implantation.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
One tablet orally once daily for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 35 mcg, followed by 7 inert tablets).
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Norethindrone: terminal elimination half-life approximately 8-11 hours. Ethinyl estradiol: terminal elimination half-life approximately 10-20 hours (mean ~13 hours). Clinical context: Steady-state achieved within 5 days; once-daily dosing maintains therapeutic levels.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Norethindrone is excreted primarily in urine as glucuronide and sulfate conjugates, with about 50-60% excreted renally; approximately 20-30% is excreted in feces via biliary elimination. Ethinyl estradiol is excreted in urine (40-60%) and feces (20-40%) after enterohepatic recirculation.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive